ReviewDiagnostics (Basel, Switzerland)2022
The Past, Present, and Future in Antinuclear Antibodies (ANA).
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Real-World Evaluation of ANA Testing Pathways: Serological Incompleteness and Comparison of Stepwise Versus Upfront Parallel Reflex Strategies.Biomedicines · 2026Article
- EGPA at Diagnosis: A Comprehensive Single-Center Profile of Laboratory Findings and Clinical Evidence.International journal of molecular sciences · 2026Article
- Autoantibody Profiles and Clinical Correlations in Systemic Sclerosis: A Cross-Sectional Study.EJIFCC · 2026Article
- Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.Chembiochem : a European journal of chemical biology · 2026Review
- Atherosclerosis features in rheumatic diseases - focus on peripheral artery disease.Frontiers in immunology · 2026Review
- More Than Just Antinuclear Antibodies: IgG Sialylation May Tip the Balance in Autoimmunity.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Analysis of antinuclear antibody pattern distribution and correlation in patients with colorectal cancer.World journal of gastrointestinal surgery · 2025Article
- Pilot Study of AI-Assisted ANA Immunofluorescence Reading-Comparison with Classical Visual Interpretation.Journal of clinical medicine · 2025Article
- Analysis of the correlation between mental status and ocular and systemic indicators in patients with primary angle-closure glaucoma.BMC ophthalmology · 2025Article
- CytoBead ANA 2 assay - a novel method for the detection of antinuclear antibodies.Scientific reports · 2025Article
- Clinical relevance and frequency of cytoplasmic patterns observed in ANA-Hep-2: experience of Cairo University Hospitals.Immunologic research · 2024Observational
- Assessing serum anti-nuclear antibodies HEp-2 patterns in synucleinopathies.Immunity & ageing : I & A · 2024Article
- Article
- Article
- Prevalence and sociodemographic correlates of antinuclear antibody testing by indirect immunofluorescence or solid-phase assays in a Spanish population: the Camargo Cohort.Immunologic research · 2024Article
- Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.Frontiers in immunology · 2024Review
- Article
- Doubtful Clinical Value of Subtyping Anti-U1-RNP Antibodies Regarding the RNP-70 kDa Antigen in Sera of Patients with Systemic Lupus Erythematosus.International journal of molecular sciences · 2023Article
- The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention.Current opinion in immunology · 2023Review
- A patient with MELAS syndrome combined with autoimmune abnormalities: a case report.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantibodies are a hallmark of autoimmunity and, specifically, antinuclear antibodies (ANAs) are the most relevant autoantibodies present in systemic autoimmune rheumatic diseases (SARDs). Over the years, different methods from LE cell to HEp-2 indirect immunofluorescence (IIF), solid-phase assays (SPAs), and finally multianalyte technologies have been developed to study ANA-associated SARDs. All of them provide complementary information that is important to provide the most clinically valuable information. The identification of new biomarkers together with multianalyte platforms will help close the so-called "seronegative gap" and to correctly classify and diagnose patients with SARDs. Finally, artificial intelligence and machine learning is an area still to be exploited but in a next future will help to extract patterns within patient data, and exploit these patterns to predict patient outcomes for improved clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.